Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer
Doyle HA, Gee RJ, Masters TD, Gee CR, Booth CJ, Peterson-Roth E, Koski RA, Helfand SC, Price L, Bascombe D, Jackson D, Ho R, Post GR, Mamula MJ. Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer. Translational Oncology 2021, 14: 101205. PMID: 34419682, PMCID: PMC8379704, DOI: 10.1016/j.tranon.2021.101205.Peer-Reviewed Original ResearchEpidermal growth factor receptorAnti-tumor immunityMonoclonal antibody therapyEGFR/HER2Antibody therapyPhase I/II open label studyCanine cancersHuman epidermal growth factor receptorImmune modifying therapiesOpen-label studyCD8 T cellsHuman cancersStandard cancer therapiesProgression of diseaseInhibited tumor growthSpontaneous canine cancersGrowth factor receptorMonoclonal therapyCheckpoint inhibitorsModifying therapiesIgG depositionObjective responseVaccine therapyMetastatic sitesAntigen response